Anti-CDK1(C22-63R)

Anti-CDK1(C22-63R)

  • $335.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the 34kDa cdc2 protein

Cited Applications :ELISA, IHC, IP, WB
Ideal working dilutions for each application should be empirically determined by the investigator.

Cross Reactivity :Human, Rat and Mouse

Host Isotype / Clone# :Rabbit, Antiserum

Immunogen :The antibody was produced against synthesized peptide corresponding to the C-terminus of the human protein conjugated to KLH.

Formulation :0.01% (w/v) Sodium Azide

Purification :Delipidation and Defibrination

Stability :1yr at –20oC from date of shipment

Sample Data :Western blot using Anti-CDK1 antibody to detect CDK1 in MCF-7 cell lysates.

Scientific Background :CDK1 or Cell Division Control protein 1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. CDK1 is a catalytic subunit of a protein kinase complex, called the M-Phase Promoting Factor that induces entry into mitosis and is universal among eukaryotes (1). Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer has also been demonstrated (2)

References :
1. Vantieghem, A. et al: Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J. Biol. Chem. 2002; 277(40):37718-31. 

2. Rigas, A.C. et al: Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007; 18.

Product Sheets (By Lot #) :

B3216-27.pdf

Research Areas :Cancer, Cell Cycle, Ser/Thr Kinases